Researchers have identified 27 new genomic variants associated with conditions such as blood pressure, type II diabetes, cigarette use and chronic kidney disease in diverse populations. The team collected data from 49,839 African-American, Hispanic/Latino, Asian, Native Hawaiian, Native American and people who identified as others and were not defined by those ethnic groups. The study aimed to better understand how genomic variants influence the risk of forming certain diseases in people of different ethnic groups.
Research supported by the Accelerating Medicines Partnership (AMP) on Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) provides new insights into tissue damage for these autoimmune conditions. These discoveries set the stage for uncovering potential drug target candidates that could advance to experimental treatments. Results of the studies were published today (June 18, 2019) in three papers in Nature Immunology.
Researchers will review findings on implications for health and care of newborns at the final public session of the National Human Genome Research Institute's Newborn Sequencing in Genomic Medicine and Public Health (NSIGHT) program. NSIGHT investigators will present their work addressing the challenges and opportunities associated with the possible use of genomic sequence information for the care of newborns.
A new study shows that the complement system, part of the innate immune system, plays a protective role to slow retinal degeneration in a mouse model of retinitis pigmentosa, an inherited eye disease. This surprising discovery contradicts previous studies of other eye diseases suggesting that the complement system worsens retinal degeneration. The research was performed by scientists at the National Eye Institute (NEI), part of the National Institutes of Health, and appears in the Journal of Experimental Medicine.
Scientists have used human skin cells to create what they believe is the first cerebral organoid system, or 'mini-brain,' for studying sporadic Creutzfeldt-Jakob disease (CJD). CJD is a fatal neurodegenerative brain disease of humans believed to be caused by infectious prion protein. The researchers, from NIH's National Institute of Allergy and Infectious Diseases, hope the human organoid model will enable them to evaluate potential CJD therapeutics and provide greater detail about human prion disease subtypes.
A new study has found that the sex or pregnancy history of red blood cell donors does not influence the risk of death among patients who receive their blood. The study adds to a growing body of literature examining whether blood donor characteristics such as sex, age, and pregnancy history affect the survival of transfused patients.
Sleeping with a television or light on in the room may be a risk factor for gaining weight or developing obesity, according to scientists at the National Institutes of Health. The research, published online June 10 in JAMA Internal Medicine, is the first to find an association between sleeping with artificial light at night and weight gain in women. The results suggest that cutting off lights at bedtime could reduce women's chances of becoming obese.
In the eternal search for understanding what makes us human, scientists found that our brains are more sensitive to pitch, the harmonic sounds we hear when listening to music, than our evolutionary relative the macaque monkey. The study, funded in part by the National Institutes of Health, highlights the promise of Sound Health, a joint project between the NIH and the John F. Kennedy Center for the Performing Arts that aims to understand the role of music in health.
A set of clinical trials examining youth and adults with type 2 diabetes or impaired glucose tolerance has found that disease progression in adults slowed during medical treatment but resumed after treatment stopped. Youth on the same treatment had markedly poorer outcomes with continued disease progression both during and after the treatment.
A treatment affecting the immune system effectively slowed the progression to clinical type 1 diabetes in high risk individuals, according to findings from National Institutes of Health-funded research. The study is the first to show that clinical type 1 diabetes can be delayed by two or more years among people who are at high risk.